US8263082B2ExpiredUtilityA1

Chemically programmable immunity

Assignee: MULLIS KARYPriority: Dec 22, 1999Filed: Jan 11, 2010Granted: Sep 11, 2012
Est. expiryDec 22, 2019(expired)· nominal 20-yr term from priority
Inventors:Kary B. Mullis
A61P 31/00A61P 37/04A61P 37/00A61K 2039/541A61K 2039/6025A61K 2039/627A61K 39/07C07K 2317/55A61K 2039/505A61K 39/385C07K 16/1242Y02A50/30
74
PatentIndex Score
3
Cited by
132
References
16
Claims

Abstract

Methods and compositions for immediately immunizing an individual against any molecule or compound. The present invention comprises an immunity linker with at least two sites; (1) at least one first binding site that binds to an immune response component in an individual that has been pre-immunized with a universal immunogen, and (2) at least one second binding site that binds specifically to a desired compound or molecule, the target.

Claims

exact text as granted — not AI-modified
1. A method of increasing a humoral immune response to a target in an individual comprising,
 administering to the individual an effective amount of a composition comprising one or more immunity linkers, 
 wherein the linkers comprise at least one first binding site and at least one second binding site, 
 wherein the first binding site binds to any humoral immune response component of a pre-existing immune response, 
 wherein the second binding site binds to the target, and 
 wherein the target normally elicits a cellular immune response in the individual. 
 
     
     
       2. The method of  claim 1 , wherein the target is a cancer cell or viral infected cell. 
     
     
       3. The method of  claim 1 , wherein the target is a cancer cell. 
     
     
       4. The method of  claim 1 , wherein the at least once second binding site is an aptamer nucleic acid. 
     
     
       5. The method of  claim 1 , wherein the one or more immunity linkers comprise, two or more first binding sites that differ in
 a) specificity for different sub-structures on the immune response component, or 
 b) affinity for the same sub-structures on the immune response component. 
 
     
     
       6. The method of  claim 1 , wherein the at least one second binding site comprises an antibody or a fragment thereof. 
     
     
       7. The method of  claim 1 , wherein the one or more immunity linkers comprise two or more second binding site that differ in
 a) specificity for different epitopes on the target, or 
 b) affinity for the same epitope on the target. 
 
     
     
       8. A method of tuning or tailoring a humoral or innate immune response to a target in an individual comprising,
 administering to the individual an effective amount of a composition comprising one or more immunity linkers, 
 wherein the linkers comprise at least one first binding site that binds to any humoral or innate immune response component of a pre-existing immune response, 
 further comprising at least one second binding site that binds to the target, and wherein the target normally elicits a cellular immune response in the individual. 
 
     
     
       9. The method of  claim 8 , wherein the target is a pathogen. 
     
     
       10. The method of  claim 8 , wherein the target is an altered cell. 
     
     
       11. The method of  claim 10 , wherein the altered cell is a cancer or viral infected cell. 
     
     
       12. The method of  claim 8 , wherein the at least one second binding site comprises an aptamer nucleic acid. 
     
     
       13. The method of  claim 8 , wherein the at least one second binding site comprises an antibody or a fragment thereof. 
     
     
       14. The method of  claim 8 , wherein the one or more immunity linkers comprise two or more first binding site that differ in
 a) specificity for different sub-structures on the immune response component, or 
 b) affinity for the same sub-structures on the immune response component. 
 
     
     
       15. The method of  claim 14 , wherein the immune response component comprises an antibody. 
     
     
       16. The method of  claim 8 , wherein the one or more immunity linkers comprise two or more second binding site that differ in
 a) specificity for different epitopes on the target, or 
 b) affinity for the same epitope on the target.

Join the waitlist — get patent alerts

Track US8263082B2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.